You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Spondyloarthritis - treatment
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kvien T, Deodhar A, Gossec L, et al
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
Annals of the Rheumatic Diseases 2017;76:355-356.